Cytocom, Inc. CBLI
Day range unavailable
52-week range unavailable
- Market cap
- 226.39M
- Shares out
- 33.96M
- Earnings date
- Aug 16, 2021
Key statistics
- Enterprise value
- 79.97M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 151.91K
- Total debt
- 2.00M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 3.62
- 200-day average
- 3.62
Next earnings
Aug 16, 2021
Expected Aug 16, 2021. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 16, 2021 | Jun 1, 2021 | 0.00 | — | — | — |
| Aug 14, 2020 | Jun 1, 2020 | 0.00 | — | — | — |
| May 15, 2020 | Mar 1, 2020 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 24, 2014 | Cantor Fitzgerald | down | Buy | Hold |
| Mar 21, 2013 | Cantor Fitzgerald | init | — | Buy |
| Mar 20, 2013 | Cantor Fitzgerald | init | — | Buy |
| Dec 6, 2012 | Oppenheimer | init | — | Outperform |
| Dec 4, 2012 | Burrill & Company | init | — | Market Outperform |
About Cytocom, Inc.
Cytocom, Inc., a clinical-stage biopharmaceutical company, develops novel small molecule immunotherapies targeting cancer, autoimmune, inflammatory, and infectious diseases. Its platform, Advanced Immunomodulating Multi-receptor System (AIMS), offers noroxymorphone analogs multi-receptor modulating therapies and proenkephalin analogs multi-receptor modulating therapies. The company also has various clinical-stage development programs, including CYTO-200 for Crohn's disease, fibromyalgia, multiple sclerosis, and covid-19; CYTO-400 for hepatocellular and pancreatic cancer; and CYTO-600 for acute radiation syndrome, advanced solid tumors, and vaccine adjuvant. Cytocom, Inc. has a collaboration agreement with the La Jolla Institute for Immunology for research and development of new immune-modulating agents targeting toll-like receptors for the treatment of cancer, infectious, autoimmune, and chronic inflammatory diseases. The company is based in Fort Collins, Colorado.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cytocom.com
News
Stocks That Hit 52-Week Highs On Wednesday 
Stocks That Hit 52-Week Highs On Thursday 
60 Biggest Movers From Yesterday 
12 Healthcare Stocks Moving In Tuesday's Intraday Session - 50 Stocks Moving In Tuesday's Mid-Day Session
136 Biggest Movers From Yesterday - 95 Biggest Movers From Yesterday
77 Biggest Movers From Yesterday 
55 Stocks Moving In Monday's Mid-Day Session - 71 Biggest Movers From Yesterday
Your note
Sign in to keep a note on CBLI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARONSTAM PETER | Chief Financial Officer | Stock Award(Grant) | Jul 26, 2021 | 141,370 |
| BROWN JULIA R | Director | Stock Award(Grant) | Jan 7, 2015 | 116,482 |
| BUCKHEIT ROBERT | Chief Technology Officer | Stock Award(Grant) | Jul 26, 2021 | 24,378 |
| DICORLETO PAUL E | Director | Stock Award(Grant) | Jun 18, 2013 | 41,968 |
| HOHN DAVID C | Director | Stock Award(Grant) | Mar 12, 2014 | 43,049 |
| MCAVOY COZETTE M | Officer | Stock Award(Grant) | Jul 26, 2021 | 60,947 |